Abstract Details

Title Early Neuropsychological Markers of Cognitive Involvement in Multiple Sclerosis

Topic Multiple Sclerosis

Presentation(s) S10 - Multiple Sclerosis: Biomarkers and Outcome Measures (4:42 PM-4:54 PM)

Poster/Presentation
Number 007

Objective To compare brief screening approaches for early, sensitive and repeatable detection of cognitive involvement in multiple sclerosis (MS).

Background Cognitive changes are common in individuals with MS, and significantly contribute to occupational status and quality of life. Measures of attention, working memory, learning, and processing speed have been traditionally considered as primary indicators of cognitive involvement in MS. More recently, it has been suggested that intra-individual variability (IIV) is a more sensitive marker of early cognitive changes in MS.

Design/Methods We compared multiple cognitive measures in individuals with early stages of relapsing-remitting MS and matched healthy controls. Tests administered included the Brief International Cognitive Assessment in MS (BICAMS), simple and choice reaction time and working memory measured with Cogstate (a computerized battery of cognitive tasks), and the Attention Network Test-Interaction (ANT-I). IIV was calculated across the trial reaction times for the ANT-I (ANT-I IIV) and Cogstate tasks. These measures were compared with a real-world measure of cognitive functioning, the Test of Everyday Cognitive Ability (TECA).

Results MS participants (n=25, mean age=26.15 ±5.18, disease duration=5.82±3.65, median EDSS=2.0) and demographically matched healthy controls (n=29, mean age=23.78 ± 7.73) completed cognitive testing in one session. Choice reaction time (Cogstate Identification task; IDN), ANTI-I IV, and TECA were the most sensitive measures to differentiate between the groups (p=.001, i>=.009 respectively).

Conclusions Brief, repeatable, computer-based administration of a choice reaction time and variability can provide the most sensitive detection of early cognitive involvement due to MS. Even mild cognitive changes early in the disease correspond with real-world impairment in activities of daily living. Early detection of disease progression is critical for intervention and prevention of further decline.

Authors/Disclosures
Tehila Eilam-Stock, PhD (NYU Langone Health) PRESENTER	Dr. Eilam-Stock has nothing to disclose.
Michael Shaw	No disclosure on file
Lauren B. Krupp, MD, FAAN (NYU Langone Medical Center)	Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Myers Squibb. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Celgene. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EBIX. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman LaRoche. Dr. krupp has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for MMMK. Dr. krupp has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Patrick, Dolan, and Kaufman. Dr. krupp has received intellectual property interests from a discovery or technology relating to health care.
Leigh E. Charvet, PhD (NYU Langone)	Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Johnson & Johnson. Dr. Charvet has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Springer Healthcare. Dr. Charvet has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for YBrain. Dr. Charvet has stock in Johnson&Johnson.

��ɫ��

��ɫ��